Hyperamylasemia

A condition with abnormally elevated level of AMYLASES in the serum. Hyperamylasemia due to PANCREATITIS or other causes may be differentiated by identifying the amylase isoenzymes.

Also Known As:

Networked: 637 relevant articles (39 outcomes, 48 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Pancreatitis
2.	Abdominal Pain (Pain, Abdominal)
3.	Edema (Dropsy)
4.	Hyperamylasemia
5.	Renal Insufficiency (Renal Failure)

Experts

1.	Bannone, Elisa: 3 articles (04/2022 - 01/2021)
2.	Bassi, Claudio: 3 articles (04/2022 - 01/2021)
3.	Büchler, Markus W: 3 articles (04/2022 - 01/2021)
4.	Hackert, Thilo: 3 articles (04/2022 - 01/2021)
5.	Loos, Martin: 3 articles (04/2022 - 01/2021)
6.	Marchegiani, Giovanni: 3 articles (04/2022 - 01/2021)
7.	Salvia, Roberto: 3 articles (04/2022 - 01/2021)
8.	Strobel, Oliver: 3 articles (04/2022 - 01/2021)
9.	Li, Zhao-Shen: 3 articles (05/2015 - 01/2007)
10.	Bhatia, Madhav: 3 articles (05/2009 - 04/2005)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Hyperamylasemia:

1.	AmylasesFDA Link 09/01/1977 - "2. This hyperamylasemia is caused by the formation of a high molecular HES-amylase complex, which cannot be easily eliminated. " 01/01/1977 - "On remission, however, hyperamylasemia due to high S-amylase activity has been found. " 05/01/1995 - "Marked fluctuation in serum amylase, ranging from 115 to 1160% in this study, may occur in patients with macroamylasemia. " 08/01/1992 - "This study was undertaken to investigate the incidence of postoperative hyperamylasemia and amylase levels of intraperitoneal drainage in 106 patients undergoing major abdominal surgery. " 02/01/1979 - "[A case report of macroamylasemia and studies on the characteristics of binding between amylase and binding substances (author's transl)]."
2.	CeruletideIBA 06/01/2000 - "In NK1-R knockout mice, the effects of cerulein on pancreatic plasma extravasation and hyperamylasemia were reduced by 60%, and pancreatic MPO by 75%, as compared to wildtype animals. " 12/01/1996 - "Marked hyperamylasemia developed immediately after cerulein administration. " 06/01/1993 - "In the group receiving both cerulein and PYY, the hyperamylasemia was attenuated with a return to basal values at 24 hours (1,206 +/- 103 U/L). " 03/01/1990 - "Marked hyperamylasemia developed in all rats immediately after administration of caerulein. " 10/01/2002 - "Caerulein significantly increased MPO activity and wet-to-dry weight ratio, produced histological evidence of edematous pancreatitis, induced plasma extravasation, and caused hyperamylasemia. "
3.	CreatinineIBA 06/01/2002 - "There was no clear correlation between hyperamylasemia and increased creatinine levels. " 01/01/1987 - "The presence of macroamylasemia can be suspected when a patient has low renal clearance of amylase relative to creatinine (Cam/Ccr). " 07/01/1987 - "Hyperamylasemia was present in 34 children; elevated amylase/creatinine clearance ratio was helpful in diagnosing ten others. " 11/01/2023 - "The ratio of renal amylase clearance to creatinine clearance was calculated at <1%, consistent with macroamylasemia. " 12/13/2013 - "Urinary amylase/urinary creatinine ratio (uAm/uCr)--a less-invasive parameter for management of hyperamylasemia."
4.	IsoamylaseIBA 05/01/1982 - "The purpose of this study was to determine if routine isoamylase assay would provide valuable diagnostic information in patients with hyperamylasemia. " 10/06/2015 - "A hyperamylasemia was noted, and further characterised by a fractionated isoamylase test, as being predominantly of the salivary type. " 05/01/1998 - "Hyperamylasemia occurred from 6 to 24 hours after the CABG and was mainly caused by pancreatic isoamylase. " 05/01/1995 - "The most useful and accurate method for distinguishing pancreatic from salivary-type hyperamylasemia is isoamylase analysis by electrophoresis. " 08/01/1992 - "2. The isoamylase pattern of postoperative hyperamylasemia was dominant in the salivary type. "
5.	macroamylaseIBA 11/01/2008 - "Macroamylasemia occurs with the formation of macroamylase complexes that cannot be cleared via renal excretion. " 03/01/1995 - "Failure to identify macroamylase as the cause of unexplained but benign hyperamylasemia correctly, can lead to costly studies (e.g. " 01/01/1993 - "It is of great importance to be able to distinguish hyperamylasemia linked to a pathological condition of the pancreas from one due to the presence of the macroamylase in the serum of the patient. " 08/01/1986 - "The contribution made by macroamylase to the occurrence of hyperamylasemia of unknown origin has not been previously quantitated nor has the distribution of age and sex been identified in a large sample. " 08/01/1982 - "A rapid and simple assay to determine if macroamylase is the cause of hyperamylasemia."
6.	Octreotide (Sandostatin)FDA LinkGeneric 01/01/2000 - "Prophylactic octreotide, in the regimen used in this study, does not protect against post-ERCP hyperamylasemia and hyperlipasemia. " 12/01/1994 - "Controlled trial of different dosages of octreotide in the prevention of hyperamylasemia induced by endoscopic papillosphincterotomy." 07/01/2009 - "The occurrence rate of hyperamylasemia was lower in the QYD group and the octreotide group than in the control group (P < 0.05). " 01/01/2007 - "Hyperamylasemia was assessed in 14 of 33 (42.4%) administered octreotide patients. " 01/01/2007 - "The results indicate that octreotide can prevent PEP and hyperamylasemia."
7.	Gabexate (Foy)IBA 01/01/2006 - "The incidence of hyperamylasemia was 33 patients (33.7%) in the gabexate group and 42 (43.7%) in the placebo group (P = 0.133). " 01/01/1991 - "Comparison of the mortality and morbidity between the two groups, early vs late administration of FOY, led to the following conclusions: (1) Early administration of FOY significantly improved mortality (29.4 vs 83.3%) in severe AP, although the improvement in mortality was not directly proportional to the shortening of the time lag between the onset of AP and the start of FOY, and (2) earlier administration of FOY brought about significantly earlier recovery of abdominal pain, hyperamylasemia, and leucocytosis in mild to moderate AP." 01/01/2006 - "The objective of the present study was to determine the efficacy of prophylactic administration of gabexate for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis, hyperamylasemia and pancreatic pain. " 01/01/2010 - "The usefulness of gabexate mesilate was not apparent in any of the following conditions: acute pancreatitis (control 5.7 vs. 4.8% for gabexate mesilate), hyperamylasemia (40.6 vs. 36.9%), and abdominal pain (1.7 vs. 8.9%). " 02/12/2007 - "When the RCTs were analyzed, odds ratios (OR) for gabexate mesilate were 0.67 [95% CI (0.31 to approximately 1.47), p = 0.32] for PEP, 3.78 [95% CI (0.62 to approximately 22.98), p = 0.15] for severe PEP, 0.68 [95% CI (0.19 to approximately 2.43), p = 0.56] for the case-fatality of PEP, 0.88 [95% CI (0.72 to approximately 1.07), p = 0.20] for post-ERCP hyperamylasemia, 0.69 [95% CI (0.39 to approximately 1.21), p = 0.19] for post-ERCP abdominal pain, thus indicating no beneficial effects of gabexate on acute pancreatitis, the death rate of PEP, hyperamylasemia and abdominal pain. "
8.	Starch (Cornstarch)IBA 06/01/1977 - "The extent of hyperamylasemia is dependent on the intravascular remission duration of the hydroxyethyl-starch preparation used. " 10/01/1980 - "Macroamylasemia induced by hydroxyethyl starch--confirmation by gel filtration analysis of serum and urine." 09/01/1977 - "Hydroxyethyl starch-induced macroamylasemia." 06/01/1977 - "[Hyperamylasemia following infusion of hydroxyethyl starch with different molecular weight distributions]." 02/01/1982 - "This hyperamylasemia is caused by the formation of a high molecular hydroxyethyl starch-amylase complex, which cannot be eliminated easily. "
9.	ginkgolide BIBA 04/01/1995 - "The positive effects of BN 52021 were expressed by: (1) Significant reduction of hyperamylasemia accompanied by lower malondialdehyde accumulation in pancreatic tissue; (2) Prevention of sulflhydryl groups depletion in lung tissue; (3) Diminution of necrotic and inflammatory changes in pancreatic tissue; and (4) Improvement of survival rate. " 01/01/1991 - "The effect of BN 52021 was expressed by significant reduction of pancreas edema, diminution of hyperamylasemia, lack of superoxide dismutase activity depletion, and inhibition of lipid peroxidation in pancreatic tissue. "
10.	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 05/01/2015 - "This study showed that somatostatin was effective and safe for the prevention of PEP and hyperamylasemia in ERCP patients.(ClinicalTrials.gov number, NCT01431781)." 07/01/2013 - "This study aimed to examine whether high-dose, long-term continuous infusion of somatostatin can reduce the incidence of PEP and post-ERCP hyperamylasemia. " 11/01/2015 - "The beneficial effect of somatostatin, in reducing the incidence of postprocedural hyperamylasemia seems of marginal clinical significance. " 07/01/2013 - "High-dose, long-term continuous infusion (0.5 mg/h for 24 hours) of somatostatin, performed as either a pre- or post-ERCP, can reduce the incidence of hyperamylasemia, but not PEP." 07/01/2013 - "The rate of post-ERCP hyperamylasemia was 19.4% (7/36), 21.3% (10/47), and 46.3% (19/41) in the pre-ERCP somatostatin, post-ERCP somatostatin, and placebo groups, respectively (P = 0.011). "

Therapies and Procedures

1.	Therapeutics 11/10/2004 - "Symptoms and hyperamylasemia improved with supportive therapy. " 10/01/2023 - "Their combinational therapy produces a synergistic effect and can reduce the incidence of hyperamylasemia, thereby improving patients' quality of life within 6 h and is also effective against individuals who received a more complicated, longer-duration ERCP and were expected to have severer and longer post-operative abdominal pain." 01/01/1989 - "Use of this method will help locate the source of hyperamylasemia in various diseases and will thus specify the diagnosis, ruling out the useless therapy for pancreatitis." 12/01/1988 - "We found no relationship of hyperamylasemia to disease site, activity, and duration or therapy and no patient developed clinical evidence of pancreatitis. " 01/01/2020 - "Adverse events occurred in 20 (18.7%) patients, including post-ERCP pancreatitis (3.7%), hyperamylasemia (12.1%), and infection of biliary tract (2.8%); all of the adverse events were mild and alleviated by conventional therapies.ERCP is an appropriate choice for pancreaticobiliary diseases in patients with ectopic papilla of Vater due to its high efficacy and safety. "
2.	Stents 06/28/2015 - "PD stent placement can reduce postoperative hyperamylasemia and might be an effective and safe option to prevent PEP if the operation indications are well controlled." 06/14/2018 - "Stent insertion up to the pancreatic body or tail reduces the risk of post-ERCP hyperamylasemia and may reduce the risk of PEP." 06/14/2018 - "Of the risk factors for post-ERCP hyperamylasemia (≥ p-AMY median, 131 IU/L), procedure time ≥ 60 min [odds ratio (OR) 2.65, 95%CI: 1.17-6.02, P = 0.02) and stent insertion into the pancreatic head (OR 3.80, 95%CI: 1.12-12.9, P = 0.03) were identified as independent risk factors by multivariate analysis. " 08/01/2015 - "In addition, difficult cannulation (OR 1.990) and pancreatography (OR 2.009), age <60 years (OR 1.294), prior diabetes (OR 0.614), biliary duct stent placement (OR 1.884) and nasobiliary drainage (OR 1.613) were associated with developing hyperamylasemia. " 04/01/2014 - "The number of cannulations more than 4 (19 patients), (p=0.006; RR= 3.00) was associated significantly with the development of hyperamylasemia and the placing of biliary stent (14 patients), (p=0.00; RR= 0.39) was a protective factor. "
3.	Drug Therapy (Chemotherapy) 10/01/1990 - "After chemotherapy, the abnormal macroamylasemia and hyperglobulinemia disappeared." 10/01/1995 - "These findings are important to consider in the differential diagnosis of hyperamylasemia following post-chemotherapy retroperitoneal lymph node dissection." 05/01/2016 - "Case report with correlation analysis between hyperamylasemia and small cell lung cancer while considering immunohistochemistry study and response to chemotherapy. " 10/01/1995 - "Extended retraction of the pancreas during post-chemotherapy retroperitoneal lymph node dissection may cause a minor reversible injury to the pancreas expressed as hyperamylasemia, hyperlipasemia and, rarely, jaundice. " 10/01/1995 - "Postoperative hyperamylasemia was evaluated in patients undergoing post-chemotherapy retroperitoneal lymph node dissection for testis cancer. "
4.	Ligation 01/01/1997 - "After 4, 8, and 24 hr of bile-pancreatic duct ligation, hyperamylasemia and histologic changes of acute pancreatitis were observed in both C5-deficient and C5-sufficient mice. " 02/01/1996 - "After 6, 24, and 48 hr of bile-pancreatic duct ligation, hyperamylasemia and acute morphologic changes of acute pancreatitis were observed. " 02/01/1996 - "Ligation of the common bile-pancreatic duct induces hyperamylasemia and acute pancreatitis in rats. " 07/01/1992 - "Transient pancreatic edema and progressive hyperamylasemia were noted within 6 hours of pancreatic and bile duct ligation. " 05/01/1991 - "Bile duct ligation resulted in significant hyperamylasemia, pancreas gland edema, inflammation, hyperglucagonemia, hypercholecystokinemia, and hypoinsulinemia. "
5.	Pancreatectomy 02/06/2023 - "We aimed to analyze the predictive value of hyperamylasemia after pancreatectomy for morbidity and for the decision to perform rescue completion pancreatectomy (CP) in a retrospective cohort study. " 01/01/2021 - "The clinical relevance of hyperamylasemia after distal pancreatectomy (DP) remains unclear and no internationally accepted definition of postoperative acute pancreatitis (POAP) exists. " 07/01/2019 - " incidence rate of clinically related pancreatic fistula (15.1% vs.2.5%, P<0.01) , grade B/C post pancreatectomy hemorrhage (8.8% vs. 2.5%, P<0.01) , and surgical site infection (9.2% vs. 3.3%, P=0.04) was significantly higher in the hyperamylasemia group.The" 10/01/1990 - "We performed this test on 67 healthy controls and 133 patients: 15 with acute pancreatitis, 53 with chronic pancreatitis (20 during painful relapse and 33 in clinical remission), 18 with pancreatic cancer, 41 with nonpancreatic disease with abdominal pain, five with macroamylasemia, and one with total pancreatectomy. " 01/01/2022 - "Hyperamylasemia grade versus drain fluid amylase: which better predicts pancreatectomy outcomes?"